Skip to main content
SpringerLink
Log in

Advanced Glycation Endproducts (AGEs) and Chronic Complications in Diabetes

  • Living reference work entry
  • First Online:
Principles of Diabetes Mellitus

Abstract

This review presents insights on the suppression of specific factors of host defense mechanisms with an emphasis on the effects of exogenous AGEs. The data are derived from studies of humans and mice. We propose that the loss of these defenses is the driving force behind the increased oxidative stress and the pathogenesis of both T1DM and T2DM and their complications. Two components of a complex and powerful homeostasis system that provide cell-protective liaisons between cellular AGE receptors (AGER1) and the NAD + -dependent deacetylase sirtuin 1 (SIRT1) are highlighted. An imbalance between host defenses and increased oxidant challenges from the environment appear to form the basis of cell injury that underlies diabetes mellitus. We introduce the concept that reduced levels of AGEs, either by restriction in the diet or by the use of agents block the action(s) of uptake of AGEs as novel cost-efficient strategies in the prevention and treatment of the current diabetes epidemic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Ward RA, McLeish KR. Methylglyoxal: a stimulus to neutrophil oxygen radical production in chronic renal failure? Nephrol Dial Transplant. 2004;19(7):1702–7.

    Article  CAS  PubMed  Google Scholar 

  2. Kim KM, Kim YS, Jung DH, Lee J, Kim JS. Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose. Exp Cell Res. 2012;318(2):152–9.

    Article  CAS  PubMed  Google Scholar 

  3. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, Zhu L, Neade T, Beeri M, Silverman JM, Ferrucci L, Tansman L, Striker GE, Uribarri J. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab. 2009;94(11):4483–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99(24):15596–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94(12):6474–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes. 1999;48(6):1308–15.

    Article  CAS  PubMed  Google Scholar 

  7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–20.

    Article  CAS  PubMed  Google Scholar 

  8. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. Clin Chem. 1986;32(10 Suppl):B37–41.

    CAS  PubMed  Google Scholar 

  9. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, Vlassara H. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol. 2008;173(2):327–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lind M, Garcia-Rodriguez LA, Booth GL, Cea-Soriano L, Shah BR, Ekeroth G, Lipscombe LL. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia. 2013;56:2601–8.

    Google Scholar 

  11. Linder BL, Fradkin JE, Rodgers GP. The TODAY study: an NIH perspective on its implications for research. Diabetes Care. 2013;36(6):1775–6.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7(9):526–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhao Z, Zhao C, Zhang XH, Zheng F, Cai W, Vlassara H, Ma ZA. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology. 2009;150(6):2569–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zimmerman GA, Meistrell 3rd M, Bloom O, Cockroft KM, Bianchi M, Risucci D, Broome J, Farmer P, Cerami A, Vlassara H, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A. 1995;92(9):3744–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011;34(7):1610–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Peppa M, Brem H, Cai W, Zhang JG, Basgen J, Li Z, Vlassara H, Uribarri J. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol. 2006;26(5):430–6.

    Article  CAS  PubMed  Google Scholar 

  17. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103.

    Article  CAS  PubMed  Google Scholar 

  19. Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, Vlassara H. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation. 2004;110(3):285–91.

    Article  CAS  PubMed  Google Scholar 

  20. Staprans I, Pan XM, Rapp JH, Feingold KR. Oxidized cholesterol in the diet is a source of oxidized lipoproteins in human serum. J Lipid Res. 2003;44(4):705–15.

    Article  CAS  PubMed  Google Scholar 

  21. Vlassara H, Brownlee M, Cerami A. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J Exp Med. 1984;160(1):197–207.

    Article  CAS  PubMed  Google Scholar 

  22. Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(12):2275–81.

    Article  CAS  PubMed  Google Scholar 

  23. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Thornalley PJ. Glyoxalase I­­structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans. 2003;31(Pt 6):1343–8.

    Article  CAS  PubMed  Google Scholar 

  25. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev. 2001;17(6):436–43.

    Article  CAS  PubMed  Google Scholar 

  26. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 1994;343(8912):1519–22.

    Article  CAS  PubMed  Google Scholar 

  27. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325(12):836–42.

    Article  CAS  PubMed  Google Scholar 

  28. Schmidt AM, Stern DM. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front Biosci. 2001;6:D1151–60.

    Article  CAS  PubMed  Google Scholar 

  29. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318(20):1315–21.

    Article  CAS  PubMed  Google Scholar 

  30. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993;90(14):6434–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  32. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 1996;271(17):9982–6.

    Article  CAS  PubMed  Google Scholar 

  33. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48(4):870–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Finot PA. The absorption and metabolism of modified amino acids in processed foods. J AOAC Int. 2005;88(3):894–903.

    CAS  PubMed  Google Scholar 

  35. Brands CMJ, Alink G, van Boekel M, Jongen W. Mutagenicity of heated sugar-casein systems: effect of the maillard reaction. L Agric Food Chem. 2000;48:2271–5.

    Article  CAS  Google Scholar 

  36. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab. 2007;9(3):233–45.

    Article  CAS  PubMed  Google Scholar 

  37. Vlassara H. Advanced glycosylation in nephropathy of diabetes and aging. Adv Nephrol Necker Hosp. 1996;25:303–15.

    CAS  PubMed  Google Scholar 

  38. Vlassara H, Brownlee M, Cerami A. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci U S A. 1985;82(17):5588–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Li G, Yan Q, Oen HO, Lennarz WJ. A specific segment of the transmembrane domain of Wbp1p is essential for its incorporation into the oligosaccharyl transferase complex. Biochemistry. 2003;42(37):11032–9.

    Article  CAS  PubMed  Google Scholar 

  40. He C, Koschinsky T, Sabol J, Buenting C, Liu C, Vlassara H. Mononuclear (MN) cell AGE receptor-1 (AGE-R1) mRNA expression and its relationship to diabetic complications. Diabetes (Suppl). 1997;46:48A (Abstract).

    Google Scholar 

  41. Cai W, Torreggiani M, Zhu L, Chen X, He JC, Striker GE, Vlassara H. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol. 2009;298(3):C624–34.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A. 2006;103(37):13801–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Torreggiani M, Liu H, Wu J, Zheng F, Cai W, Striker G, Vlassara H. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol. 2009;175(4):1722–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cai W, Uribarri J, Zhu L, Chen X, Swamy S, Zhao Z, Grosjean F, Simonaro C, Kuchel GA, Schnaider-Beeri M, Woodward M, Striker GE, Vlassara H. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A. 2014;111:4910–5.

    Google Scholar 

  45. Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am. 2013;42(4):697–719.

    Article  PubMed  Google Scholar 

  46. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A. 1994;91(19):8807–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108(7):949–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Cai W, He JC, Zhu L, Chen X, Wallenstein S, Striker GE, Vlassara H. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol. 2007;170(6):1893–902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med. 1995;1(6):634–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes. 2002;51(12):3353–61.

    Article  CAS  PubMed  Google Scholar 

  51. Beyan H, Riese H, Hawa MI, Beretta G, Davidson HW, Hutton JC, Burger H, Schlosser M, Snieder H, Boehm BO, Leslie RD. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes. 2012;61(5):1192–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A. 2012;109(39):15888–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol. 2009;5(7):367–73.

    Article  CAS  PubMed  Google Scholar 

  54. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46.

    Article  CAS  PubMed  Google Scholar 

  55. Willette AA, Xu G, Johnson SC, Birdsill AC, Jonaitis EM, Sager MA, Hermann BP, La Rue A, Asthana S, Bendlin BB. Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care. 2013;36(2):443–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Vlassara H, Brownlee M, Cerami A. Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes. 1983;32(7):670–4.

    Article  CAS  PubMed  Google Scholar 

  57. Beeri MS, Moshier E, Schmeidler J, Godbold J, Uribarri J, Reddy S, Sano M, Grossman HT, Cai W, Vlassara H, Silverman JM. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev. 2011;132(11–12):583–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Belanger M, Yang J, Petit JM, Laroche T, Magistretti PJ, Allaman I. Role of the glyoxalase system in astrocyte-mediated neuroprotection. J Neurosci. 2011;31(50):18338–52.

    Article  CAS  PubMed  Google Scholar 

  59. Tellez-Nagel I, Korthals JK, Vlassara HV, Cerami A. An ultrastructural study of chronic sodium cyanate-indiuced neuropathy. J Neuropathol Exp Neurol. 1977;36(2):352–63.

    Article  CAS  PubMed  Google Scholar 

  60. Cai W, Uribarri J, Zhu L, Chen X, Swamy S, Zhao Z, Grosjean F, Simonaro C, Kuchel GA, Schnaider-Beeri M, Woodward M, Striker GE, Vlassara H. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A. 2014;111(13):4940–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. West RK, Moshier E, Lubitz I, Schmeidler J, Godbold J, Cai W, Uribarri J, Vlassara H, Silverman JM, Beeri MS. Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech Ageing Dev. 2014;140:10–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Bayer J, Rune G, Kutsche K, Schwarze U, Kalisch R, Buchel C, Sommer T. Estrogen and the male hippocampus: genetic variation in the aromatase gene predicting serum estrogen is associated with hippocampal gray matter volume in men. Hippocampus. 2013;23(2):117–21.

    Article  CAS  PubMed  Google Scholar 

  63. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Vlassara H, Cai W, Chen X, Serrano EJ, Shobha MS, Uribarri J, Woodward M, Striker GE. Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift. J Gerontol A Biol Sci Med Sci. 2012;67(12):1410–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Azcoitia I, Sierra A, Veiga S, Honda S, Harada N, Garcia-Segura LM. Brain aromatase is neuroprotective. J Neurobiol. 2001;47(4):318–29.

    Article  CAS  PubMed  Google Scholar 

  66. Waheed S, Matsushita K, Astor BC, Hoogeveen RC, Ballantyne C, Coresh J. Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. Clin J Am Soc Nephrol. 2013;8(3):434–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994;91(24):11704–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Kato M, Dang V, Wang M, Park JT, Deshpande S, Kadam S, Mardiros A, Zhan Y, Oettgen P, Putta S, Yuan H, Lanting L, Natarajan R. TGF-beta induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci Signal. 2013;6(278):ra43.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care. 2007;30(7):1724–9.

    Article  CAS  PubMed  Google Scholar 

  70. Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol CJASN. 2015;10(5):759–66.

    Article  CAS  PubMed  Google Scholar 

  71. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev. 2002;18(3):224–37.

    Article  PubMed  Google Scholar 

  72. Wu J, Guan TJ, Zheng S, Grosjean F, Liu W, Xiong H, Gordon R, Vlassara H, Striker GE, Zheng F. Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice. Lab Invest. 2011;91(10):1459–71.

    Article  CAS  PubMed  Google Scholar 

  73. Beisswenger PJ, Howell SK, Russell GB, Miller ME, Rich SS, Mauer M. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care. 2013;36:3234–9.

    Google Scholar 

  74. Schwedler SB, Bobadilla N, Striker LJ, Vaamonde CA, Herrera-Acosta J, Striker GE. Pentosan polysulfate treatment reduces cyclosporine-induced nephropathy in salt-depleted rats. Transplantation. 1999;68(10):1583–8.

    Article  CAS  PubMed  Google Scholar 

  75. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X, Johnson AC, Crabtree G, Smiles AM, Mayadas TN, Warram JH, Krolewski AS. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012;23(3):516–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Schwedler SB, Gilbert T, Moreau E, Striker LJ, Merlet-Benichou C, Striker GE. Nephrotoxin exposure in utero reduces glomerular number in sclerosis-prone but not sclerosis-resistant mice. Kidney Int. 1999;56(5):1683–90.

    Article  CAS  PubMed  Google Scholar 

  77. Izumi Y, Yabe D, Taniguchi A, Fukushima M, Nakai Y, Hosokawa M, Okumura T, Nin K, Matsumoto K, Nishimura F, Nagasaka S, Seino Y. Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;99(2):145–50.

    Article  CAS  PubMed  Google Scholar 

  78. Wu J, Zhang R, Torreggiani M, Ting A, Xiong H, Striker GE, Vlassara H, Zheng F. Induction of diabetes in aged C57B6 mice results in severe nephropathy: an association with oxidative stress, endoplasmic reticulum stress, and inflammation. Am J Pathol. 2010;176(5):2163–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Stinghen AE, Massy ZA, Vlassara H, Striker GE, Boullier A. Uremic toxicity of advanced glycation end products in CKD. J Am Soc Nephrol JASN. 2016;27:354–70.

    Google Scholar 

  80. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis. 2004;43(4):690–5.

    Article  CAS  PubMed  Google Scholar 

  81. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol JASN. 2003;14(3):728–31.

    Article  CAS  PubMed  Google Scholar 

  82. Christiansen CF, Johansen MB, Christensen S, O’Brien JM, Tonnesen E, Sorensen HT. Type 2 diabetes and 1-year mortality in intensive care unit patients. Eur J Clin Invest. 2013;43(3):238–47.

    Article  CAS  PubMed  Google Scholar 

  83. Striker GE, Klahr S. Clinical trials in progression of chronic renal failure. Adv Intern Med. 1997;42:555–95.

    CAS  PubMed  Google Scholar 

  84. Jasuja GK, Travison TG, Davda M, Rose AJ, Zhang A, Kushnir MM, Rockwood AL, Meikle W, Coviello AD, D’Agostino R, Vasan RS, Bhasin S. Circulating estrone levels are associated prospectively with diabetes risk in men of the framingham heart study. Diabetes Care. 2013;36:2591–6.

    Google Scholar 

  85. Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant. 1996;11 Suppl 5:62–5.

    Article  CAS  PubMed  Google Scholar 

  86. Miyashita T, Toyoda Y, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. J Toxicol Sci. 2012;37(5):931–42.

    Article  CAS  PubMed  Google Scholar 

  87. Lupia E, Zheng F, Grosjean F, Tack I, Doublier S, Elliot SJ, Vlassara H, Striker GE. Pentosan polysulfate inhibits atherosclerosis in Watanabe heritable hyperlipidemic rabbits: differential modulation of metalloproteinase-2 and -9. Lab Invest. 2012;92(2):236–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Florentino G, Cotrim HP, Florentino A, Padilha C, Medeiros-Neto M, Bragagnol G, Schwingel P. Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease? Ann Hepatol. 2012;11(1):147–9.

    PubMed  Google Scholar 

  89. Mericq V, Piccardo C, Cai W, Chen X, Zhu L, Striker GE, Vlassara H, Uribarri J. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care. 2010;33(10):2232–7.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep. 2007;7(3):235–41.

    Article  CAS  PubMed  Google Scholar 

  91. Chetyrkin SV, Zhang W, Hudson BG, Serianni AS, Voziyan PA. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry. 2008;47(3):997–1006.

    Article  CAS  PubMed  Google Scholar 

  92. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007;85(5):1236–43.

    CAS  PubMed  Google Scholar 

  93. Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, Koschinsky T, Vlassara H. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 2007;30(10):2579–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Diabetes and Aging, Division of Geriatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Helen Vlassara

  2. Division of Nephrology, Departments of Medicine and Geriatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Gary E. Striker

Authors
  1. Helen Vlassara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary E. Striker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helen Vlassara .

Editor information

Editors and Affiliations

  1. Lenox Hill Hospital Division of Endocrinology, New York, New York, USA

    Leonid Poretsky

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this entry

Cite this entry

Vlassara, H., Striker, G.E. (2016). Advanced Glycation Endproducts (AGEs) and Chronic Complications in Diabetes. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Cham. https://doi.org/10.1007/978-3-319-20797-1_20-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20797-1_20-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Online ISBN: 978-3-319-20797-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation